Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» abrocitinib
abrocitinib
Is Pfizer About to Have Another Megablockbuster Drug in Its Lineup?
Motley Fool
Fri, 01/28/22 - 10:17 am
Pfizer
abrocitinib
atopic dermatitis
From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year
Fierce Pharma
Mon, 09/13/21 - 11:38 pm
FDA
Pfizer
Argenx
UCB Pharma
Roche
efgartigimod
bimekizumab
faricimab
abrocitinib
Pfizer's abrocitinib beats blockbuster Dupixent in phase 3 eczema trial, but key questions remain
Fierce Biotech
Mon, 08/30/21 - 11:03 am
Pfizer
abrocitinib
atopic dermatitis
Dupixent
Sanofi
Regeneron
clinical trials
FDA pushes eczema decision for Eli Lilly's Olumiant, Pfizer's abrocitinib back 3 months — raising more questions for the JAK class
Endpoints
Wed, 04/7/21 - 10:30 am
FDA
JAK inhibitors
Eli Lilly
olumiant
Pfizer
abrocitinib
eczema
Pfizer, still chasing Dupixent, releases fifth round of data for eczema JAK inhibitor abrocitinib
Endpoints
Wed, 11/11/20 - 11:04 am
Pfizer
JAK inhibitors
abrocitinib
Dupixent
atopic dermatitis
clinical trials
Pfizer may have a lot going on in immunology, but all its drugs could be beaten by rivals: analyst
Fierce Pharma
Thu, 07/9/20 - 10:21 pm
Pfizer
immunology
abrocitinib
Xeljanz
PF-06651600
Pfizer's JAK abrocitinib comes through in teen eczema test
Fierce Biotech
Wed, 06/10/20 - 10:43 am
Pfizer
abrocitinib
eczema
atopic dermatitis
clinical trials
New safety data expose potential weakness as Pfizer's abrocitinib takes on Dupixent in eczema
Endpoints
Thu, 06/4/20 - 11:15 am
Pfizer
abrocitinib
Dupixent
clinical trials
eczema
Pfizer Posts Positive Results in Two Phase III Studies, Postpones Investor Day
BioSpace
Thu, 03/19/20 - 11:12 am
Pfizer
clinical trials
atopic dermatitis
pneumococcal disease
20VPnC
vaccines
abrocitinib
Upcoming events – Pfizer's abrocitinib and Myovant's relugolix
EP Vantage
Sat, 01/11/20 - 12:01 am
Pfizer
abrocitinib
Dupixent
Sanofi
Myovant
Relugolix
uterine fibroids
Pfizer posts detailed phase 3 data on its Dupixent rival
Fierce Biotech
Sat, 10/12/19 - 12:30 pm
Pfizer
clinical trials
atopic dermatitis
abrocitinib
Dupixent
Sanofi
Regeneron
Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug
TheStreet.com
Fri, 09/27/19 - 09:29 am
Pfizer
clinical trials
eczema
abrocitinib
Pfizer jumps into the heated PhIII race for new-wave JAK inhibitors — but safety frets loom large
Endpoints
Wed, 05/15/19 - 10:24 am
Pfizer
JAK inhibitors
abrocitinib
anti-inflammatories